CA3180509A1 - Formulation comprising daprodustat - Google Patents

Formulation comprising daprodustat Download PDF

Info

Publication number
CA3180509A1
CA3180509A1 CA3180509A CA3180509A CA3180509A1 CA 3180509 A1 CA3180509 A1 CA 3180509A1 CA 3180509 A CA3180509 A CA 3180509A CA 3180509 A CA3180509 A CA 3180509A CA 3180509 A1 CA3180509 A1 CA 3180509A1
Authority
CA
Canada
Prior art keywords
tablet
immediate release
release tablet
dose
daprodustat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180509A
Other languages
English (en)
French (fr)
Inventor
Sayantan CHATTORAJ
Scott Ryan CROY
James Anderson MCLEOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3180509A1 publication Critical patent/CA3180509A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3180509A 2020-06-19 2021-06-17 Formulation comprising daprodustat Pending CA3180509A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063041403P 2020-06-19 2020-06-19
US63/041,403 2020-06-19
US202063043292P 2020-06-24 2020-06-24
US63/043,292 2020-06-24
PCT/EP2021/066386 WO2021255159A1 (en) 2020-06-19 2021-06-17 Formulation comprising daprodustat

Publications (1)

Publication Number Publication Date
CA3180509A1 true CA3180509A1 (en) 2021-12-23

Family

ID=76730508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180509A Pending CA3180509A1 (en) 2020-06-19 2021-06-17 Formulation comprising daprodustat

Country Status (7)

Country Link
US (1) US20230225977A1 (https=)
EP (1) EP4167967A1 (https=)
JP (1) JP7797425B2 (https=)
CN (1) CN115697307A (https=)
BR (1) BR112022024533A2 (https=)
CA (1) CA3180509A1 (https=)
WO (1) WO2021255159A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024521491A (ja) * 2021-06-18 2024-05-31 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットおよびその前駆体の新規な製造方法
WO2024257063A1 (en) * 2023-06-16 2024-12-19 Glenmark Life Sciences Limited Solid dispersion of daprodustat and a process for the preparation thereof
WO2025087207A1 (zh) * 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
SI3881833T1 (sl) * 2015-06-30 2024-03-29 Genentech, Inc., Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PH12018000227A1 (en) * 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
JP2020533396A (ja) 2017-09-15 2020-11-19 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド Ｇｓｋ１２７８８６３の結晶形及びその製造方法並びに医薬用途
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
EP3880663A1 (en) * 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof

Also Published As

Publication number Publication date
JP2023532223A (ja) 2023-07-27
US20230225977A1 (en) 2023-07-20
JP7797425B2 (ja) 2026-01-13
BR112022024533A2 (pt) 2022-12-27
WO2021255159A1 (en) 2021-12-23
EP4167967A1 (en) 2023-04-26
CN115697307A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
KR100645866B1 (ko) 발데콕시브 조성물
JP4084309B2 (ja) 単一の結晶形を含有する固形製剤
CA3180509A1 (en) Formulation comprising daprodustat
CA2662265A1 (en) Imatinib compositions
EP4048276B1 (en) Solid pharmaceutical formulations comprising ticagrelor
TWI903066B (zh) 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物
Parikh et al. Formulation optimization and evaluation of immediate release tablet of telmisartan
EP4058025A1 (en) Pharmaceutical compositions comprising ticagrelor
JP2021518422A (ja) レナリドミドを含む医薬組成物
CZ300047B6 (cs) Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
WO2019012552A4 (en) Compositions of ferric organic compounds
KR20180060705A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
WO2022115055A1 (en) Immediate release composition of favipiravir
WO2021117697A1 (ja) 固形製剤
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
RU2321405C2 (ru) Лекарственное средство, обладающее анальгезирующим, жаропонижающим и психостимулирующим действием, и способ его получения
CA2609026A1 (en) Formulations containing losartan and/or its salts
EP4342458A1 (en) Oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
EP4633610A1 (en) Monolayer tablet composition of empagliflozin and metformin hydrochloride
WO2024225996A1 (en) A new pharmaceutical tablet composition comprising eltrombopag olamine
TR2023006078T2 (tr) Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu
JPS6281309A (ja) バルプロ酸ナトリウム徐放錠
WO2022263899A1 (en) Novel manufacturing method of daprodustat and precursors thereof
EA049988B1 (ru) Лекарственная форма для перорального применения, содержащая 1-(3-циано-1-изопропил-индол-5-ил)пиразол-4-карбоновую кислоту
EP4213937A1 (en) Solid dosage form comprising sitagliptin and method of preparation thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260223